title: Effect of N-benzoyl-D-phenylalanine and metformin on carbohydrate metabolic enzymes in neonatal streptozotocin diabetic rats.
abstract: BACKGROUND
  The effect of N-benzoyl-D-phenylalanine (NBDP) and metformin was studied on the activities of carbohydrate metabolic enzymes in neonatal streptozotocin (nSTZ) non-insulin-dependent diabetic rats.
  
  
  METHODS
  To induce non-insulin-dependent diabetes mellitus (NIDDM), single dose injection of streptozotocin (STZ; 100 mg/kg body weight; i.p.) was given to 2-day old rats. After 10-12 weeks, rats weighing >150 g were selected for screening in NIDDM model, they were checked for fasting blood glucose concentrations to conform the status of NIDDM. NBDP (50,100 and 200 mg/kg body weight) was administered orally for 6 weeks into the confirmed diabetic rats.
  
  
  RESULTS
  The activities of gluconeogenic enzymes were significantly increased, whereas the activities of hexokinase and glucose-6-phosphate dehydrogenase were significantly decreased in nSTZ diabetic rats. Both NBDP and metformin were able to restore the altered enzyme activities to almost control concentrations. Combination treatment was more effective than either drug alone.
  
  
  CONCLUSIONS
  The administration of NBDP along with metformin to nSTZ diabetic rats normalizes blood glucose and causes marked improvement of altered carbohydrate metabolic enzymes during diabetes.
authors.affiliation: Department of Biochemistry, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu-608 002, India.
authors.forename: Natarajan
authors.initials: N
authors.lastname: Ashokkumar
authors.forename: Leelavinothan
authors.initials: L
authors.lastname: Pari
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D050260:Carbohydrate Metabolism; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology*; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology; D004435:Eating / Q000187:drug effects; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects; D005954:Glucosephosphate Dehydrogenase / Q000097:blood; D006442:Glycated Hemoglobin / Q000378:metabolism; D006019:Glycolysis / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006593:Hexokinase / Q000097:blood; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D005954:Glucosephosphate Dehydrogenase; D006442:Glycated Hemoglobin; D006454:Hemoglobins; D006593:Hexokinase; D007004:Hypoglycemic Agents; D008055:Lipids; D008112:Liver Glycogen; D008687:Metformin; D010649:Phenylalanine; C053764:benzoylphenylalanine